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Abstract
The spread of cancer cells from primary tumors to regional lymph nodes is often associated with 
reduced survival. One prevailing model to explain this association posits that fatal, distant 
metastases are seeded by lymph node metastases. This view provides a mechanistic basis for the 
TNM staging system and is the rationale for surgical resection of tumor-draining lymph nodes. 
Here, we examine the evolutionary relationship between primary tumor, lymph node and distant 
metastases in human colorectal cancer. Studying 213 archival biopsy samples from 17 patients, we 
used somatic variants in hypermutable DNA regions to reconstruct high-confidence phylogenetic 
trees. We found that in 65% of cases, lymphatic and distant metastases arose from independent 
subclones in the primary tumor, whereas in 35% of cases they shared common subclonal origin. 
Therefore, two different lineage relationships between lymphatic and distant metastases exist in 
colorectal cancer.
The spread of cancer cells from the primary tumor to regional lymph nodes is one of the 
most important factors predicting survival in patients with epithelial cancers (1). Lymph 
node metastasis uniformly associates with worse outcomes in breast (2), prostate (3), lung 
(4) and colorectal cancer (5), the most frequent cancers in the U.S. population. In colorectal 
*Corresponding author. naxerova.kamila@mgh.harvard.edu. 
Europe PMC Funders Group
Author Manuscript
Science. Author manuscript; available in PMC 2018 January 07.
Published in final edited form as:









carcinoma, the presence of cancer cells in tumor-draining lymph nodes defines stage III 
disease and triggers administration of adjuvant chemotherapy (6). The 5-year survival for 
patients with stage II (no lymph node metastases) is 82.5%, in contrast to 59.5% for patients 
with stage III disease (7).
In most patients, lymph node metastasis is not the cause of death, but is correlated with 
spread to vital organs (8). The association between lymphatic and distant metastasis has 
been known for at least 150 years (9) and, together with the observation that lymph node 
disease often precedes systemic disease, has engendered the view that affected lymph nodes 
may give rise to distant metastases (10–12). The concept of such a sequential progression or 
metastatic cascade (13), in which the primary tumor (T) seeds lymph node metastases (N), 
which in turn seed distant metastases (M), provides a mechanistic basis for the TNM staging 
system. A corollary of the sequential progression model is that surgical resection of positive 
lymph nodes will reduce recurrence rates. Indeed, resection of regional lymph nodes has 
been performed for more than 100 years (14). More recently, a number of clinical trials have 
shown that lymph node removal does not always improve patient survival (15). These 
findings have inspired the alternative view that lymph node metastases do not give rise to 
distant metastases (16) and suggest that treatment strategies may need to be re-evaluated 
(17).
Given its potential impact on patient care, a better understanding of the evolutionary 
relationship between lymph node and distant metastases is critical. We still do not know 
whether a single metastatic subclone evolves in the primary tumor, subsequently spreading 
to lymph nodes and distant sites (18–21), or whether multiple subclones in the primary 
tumor independently seed lymphatic and distant metastases (22–24). Here, we begin to 
examine these questions by studying the evolutionary history of colorectal cancer 
metastases.
Indels in hypermutable DNA enable reconstruction of tumor phylogenies
We conducted a systematic review of 1373 patient records and diagnostic materials at 
Massachusetts General Hospital (Fig. S1) and initially identified 19 colorectal cancer 
patients for whom formalin-fixed and paraffin-embedded samples from primary tumors, 
lymph node and distant metastases were available (Fig. 1A). We collected multiple tumor 
regions for each patient (mean 12.6, range 7-29) for a total of 239 samples (92 primary 
tumor biopsies, 59 lymph node metastases, 52 distant metastases, 36 normal tissue/germline 
samples) (Table S1). Of the 19 patients, 17 had liver metastases, one had an ovary 
metastasis, and one had multiple metastases in the omentum.
To trace the evolution of these cancers, we used a methodology (25) that leverages insertion/
deletion (indel) mutations in hypermutable, non-coding polyguanine repeats (Fig. S2). The 
mutation rate of polyguanine repeats is several orders of magnitude higher than the mutation 
rate of non-repetitive DNA (26), making these sequences a rich reservoir of neutral somatic 
variation. Previous work has shown that indels in polyguanine repeats (27) as well as other 
microsatellites (28) accurately reconstruct evolutionary events modeled in cell culture. 
Furthermore, in silico models of polyguanine tract evolution have demonstrated that 
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revertant or parallel mutations do not significantly affect phylogenetic reconstruction 
accuracy when the number of interrogated markers is larger than 10 (29). These properties 
make polyguanine tracts attractive tools for phylogenetic analyses. Here, the mutation 
information from 20-43 polyguanine markers was generally sufficient to resolve lineages at 
our chosen confidence threshold (clade confidence > 70%, Fig. S3 and S4). Polyguanine 
markers were distributed across many chromosomes (Table S2). Therefore, any individual 
chromosomal alteration (gain or loss) would not be expected to substantially influence 
phylogenetic reconstruction. In total, our data set consisted of 19,541 individual genotypes. 
We developed a fully automated pipeline for data filtering, noise reduction and phylogenetic 
reconstruction (supplementary methods). First, to avoid artifacts created by contamination 
with normal cells, we implemented rigorous purity criteria, eliminating 11% of specimens 
from our study (Fig. S5 and Table S1). For all specimens belonging to the same patient, we 
then calculated a pairwise distance measure, the Jensen-Shannon distance (JSD) (30), over 
all polyguanine repeats. This distance reflected how much the samples had genetically 
diverged and formed the basis of our phylogenetic reconstruction with the neighbor-joining 
method (31).
Indel mutation patterns in the colorectal cancer cohort differed among patients. 81% of all 
observed alterations were deletions and 19% were insertions. A 4:1 ratio of deletions to 
insertions has previously been described by us and others (25, 32), indicating that it is an 
inherent property of polyguanine repeats. However, among individual cancers, we observed 
a relatively wide range of deletion frequencies, ranging from 45% in patient C69 to 100% in 
patient C77 (Fig. S6). This suggests that additional determinants, such as alterations in 
specific DNA repair proteins, may contribute to a skewing of mutation patterns in individual 
tumors. For example, a cancer showing microsatellite instability due to loss of MLH1 
protein expression almost exclusively harbored deletions (Fig. 1B) that also were of a 
significantly larger size than deletions in microsatellite stable tumors (Fig. 1C, Fig. S6).
Next, we explored whether accumulation of polyguanine indels is a cancer-related process or 
whether these mutations can be found in age-matched normal intestinal stem cells (ISCs). 
We analyzed DNA from 18 clonal expansions of human ISCs. Stem cell donors for 12 of 
these expansions were children (ages 4-14) and 6 expansions were from a 66-year old adult 
(Fig. S7). Adult ISCs had diverged significantly farther from a polyclonal germline reference 
than ISCs from children (Fig. 2A), suggesting that polyguanine indels accumulate in normal 
ISCs. We also observed a significant correlation between clonal mutation frequency and 
patient age in our colorectal cancer cohort (Fig. S8). The mean clonal mutation frequency in 
normal ISCs from the 66-year-old donor was lower than the mean frequency in cancers from 
age-matched (50-69 year old) patients (Fig. 2B), but with significant overlap of the two 
distributions. The baseline polyguanine mutation burden of a colorectal cancer therefore 
partially consists of alterations that are present in all intestinal cells.
Two distinct patterns of metastatic dissemination exist in colorectal cancer
The main goal of our study was to illuminate the evolutionary relationship between 
lymphatic and distant metastases. We aimed to sample lymph nodes as comprehensively as 
possible and included 91.3% of resected positive nodes in our analysis (Fig. S9, 
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supplementary methods). We first investigated the genetic distances among lymph node 
metastases, primary tumor biopsies, and distant metastases. For 33 of 45 (73%) lymph node 
metastases, the distance to the primary tumor (Fig. 2C) was shorter than the distance to 
distant metastases, and 31 of 45 (69%) distant metastases had a shorter genetic distance to 
the primary tumor than to any lymph node metastasis (Fig. 2D). This indicates that both 
types of metastatic lesions likely originated from distinct subclones in the primary tumor in 
most cases. To test this hypothesis, we examined all phylogenetic trees according to formal 
criteria. Patients were classified into two categories based on tree topology (Fig. 2E). We 
reasoned that lymph node and distant metastases had a common origin if a patient’s tree 
contained a clade that contained at least one lymph node and at least one distant metastasis, 
but no primary tumor samples. Existence of such a branch indicates that both types of 
metastases were seeded from the same subclone, or that lymph node metastases gave rise to 
distant metastases. Formally, the reverse – seeding of lymphatic metastases from distant 
metastases – is also possible. A patient was classified as having distinct origins of lymphatic 
and distant metastases if no such clade existed. In all distinct origin cases, lymphatic and 
distant metastases were each more closely related to a primary tumor region than to each 
other.
To assess the robustness of each tumor’s origin classification, we employed a bootstrapping 
strategy. We performed repeated random sampling (n=1000) of a tumor’s mutation data to 
determine whether our origin classification was sensitive to changes in a limited number of 
polyguanine markers (supplementary methods). 14 of 17 tumors (82%) were classified with 
a bootstrap value above 80% (Fig. 2F), confirming the robustness of our phylogenetic data 
and our classification scheme. We also evaluated our classification by utilizing the 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) (33). (The nature of 
polyguanine genotyping data suggests the use of distance-based phylogenetic methods; see 
supplementary methods). Origin classification outcomes did not change for any of our 17 
patients, further demonstrating the reliability of our results (all phylogenetic trees can by 
downloaded from datadryad.org, ID xxx).
Common origin of lymphatic and distant metastases
In 6 out of 17 tumors (35%), we found common origin of lymphatic and distant metastases. 
Selected phylogenetic trees with a classification confidence score above 80% for common 
origin are displayed in Fig. 3, along with pertinent clinical information.
Patient C38’s cancer (Fig. 3A and anatomical sketch in Figure 1B) spread to the omentum 
and to the mesenteric lymph nodes. Furthermore, several satellite nodules had formed within 
the colonic epithelium, spatially separated from the primary tumor. We also investigated a 
piece of tumor that had invaded a vein. Notably, phylogenetic reconstruction showed that all 
lesions whose formation had depended on cell migration (that is, the satellite nodules, the 
distant and lymph node metastases, and the tumor within the vein) shared common ancestry, 
while the primary tumor had a divergent genetic profile.
Patient C69’s cancer (Fig. 3B) showed a similar pattern, with one metastatic subclone giving 
rise to several liver metastases and a lymph node metastasis. Polyguanine indels clearly 
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attributed all metastases to the same evolutionary branch, even though M1, M2 and L1 were 
resected several months earlier than M3, and the patient received chemotherapy and 
bevacizumab between surgeries.
Patient C58 (Fig. 3C and anatomical sketch in Fig. 1C) had widespread metastases to the 
mesenteric lymph nodes and the liver. Most lymph node metastases were closely related to 
the primary tumor. However, a distinct subclone had formed in several lymph nodes that 
were located in close anatomical proximity (L3, L5, L6). The liver metastasis derived from 
the same subclone found in this lymph node group.
Further examples of patients with common origin of lymphatic and distant metastases are 
shown in Fig. 4D and Fig. S3. In all common origin cases, tree topologies are consistent 
with one of two modes of dissemination: the primary tumor seeded lymph node metastases, 
which in turn seeded distant metastases, with the formal possibility of the reverse. Or one 
genetically distinct ancestor evolved within the primary tumor and subsequently colonized 
lymph nodes and distant sites. In both scenarios, lymphatic and distant metastases share a 
common origin.
The common origin category is compatible with the idea of sequential progression and can 
explain important clinical observations, such as the well-established correlation between 
lymphatic and distant disease. In a majority of patients, however, tree topologies indicated 
independent seeding of lymphatic and distant metastasis from the primary tumor.
Distinct origins of lymphatic and distant metastases
Cancers in the distinct origins group, which encompassed 11 out of 17 patients (65%), 
contained multiple, genetically distinct metastasis ancestors. Fig. 4 shows selected 
phylogenetic trees with a distinct origin classification confidence score above 80% (the 
complete set, along with confidence values for each clade, is provided in Fig. S4).
Patient C66’s tumor (Fig. 4A) is a representative example of the distinct origins category. 
The cancer harbored multiple subclones at different stages of evolution that had seeded 
genetically distinct metastases. Area P2, for example, was most closely related to lymph 
node metastasis L3, while area P1 was the origin of liver metastases M1 and M2. The tree 
shows that lymph node metastases were seeded continuously throughout the development of 
the tumor, but did not metastasize further. The liver metastases, on the other hand, arose in 
later evolution stages from the genetically most advanced clone. They constitute the 
terminal, most mutation-rich branch of the tree and, as a group, are more homogeneous than 
the lymph node metastases.
Patient C12’s tumor (Fig. 4B) partially resembled that of patient C58. Its phylogenetic tree 
also showed a group of lymph node metastases (L2, L3, L4) that either derived from the 
same ancestral clone or gave rise to each other, while other lymphatic lesions (L1) were 
seeded independently. Notably, as for C58, the closely related nodes also were in anatomical 
proximity. However, the patient’s liver metastasis (M1) did not arise from this subclone, but 
instead had distinct origins in primary tumor area P8.
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Another noteworthy case from the distinct origins group is patient C53 (Fig. 4C) who 
underwent resection of two metastases located in the right liver lobe and one metastasis in 
the left liver lobe. Phylogenetic reconstruction showed that the metastases in the right liver 
diverged relatively early. After their divergence, the primary tumor evolved further and 
independently gave rise to lymph node metastasis L1 and the left liver metastasis, M3.
Further examples of cancers in the distinct origins category are shown in Fig. 4D-F and Fig. 
S4. In all these cases, the phylogenetic data indicate that lymph node metastases were not 
the source of distant metastases (also see explanatory schematic in Fig. S10).
Common clinicopathological variables do not correlate with origin 
classification
Next, we examined whether our origin classification was correlated with (and thus 
potentially influenced by) any clinicopathologic variables. We did not observe any 
significant differences in the number of positive nodes, the ratio of positive to examined 
nodes, the number of lymph nodes included in the final data set, the number of excluded 
nodes (Fig. S11A-D), the number of sampled primary tumor regions, the percentage of T3 
vs. T4 stage patients (no T1/2 stage tumors were part of this cohort), the distribution of 
primary tumor sizes, the presence of vascular invasion, or the fraction of patients with 
synchronous vs. metachronous distant metastasis (Fig. S12A-E) between origin categories.
Most importantly, we found no association between origin and treatment history. Only one 
patient (C77) had neo-adjuvant chemotherapy (Table S3). In six patients, distant metastases 
were resected after the primary tumor and the lymph node metastases had already been 
removed, and all received treatment in the intervening time interval. Three of these patients 
(C69, C65, C36) fell into the common, and three (C66, C39, C63) into the distinct origins 
category (p=0.6).
Discussion
The presence of lymph node metastases is an important prognostic factor for most cancers, 
but the underlying reason has been unclear. One prevailing model posits that lymph node 
metastases are precursors of distant metastases and their surgical resection is necessary to 
attain a “cancer-free” state (34). An alternative model posits that distant metastases arise 
independently of lymph node metastases (16).
Our data show that lymph node metastases and distant metastases indeed often do have a 
common origin. While our phylogenies do not allow us to distinguish between sequential 
progression and common subclonal origin, many phylogenies in the common origin category 
are compatible with seeding of distant metastases from lymph nodes.
However, in a majority of patients, we find strong evidence of independent origins of lymph 
node and distant lesions. If independent seeding is prevalent, what is the reason for the 
association of lymphatic and distant metastasis? It could be that the association is driven by 
the common origin subset of patients. An alternative possibility is that most cells in tumors 
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belonging to the distinct origins category have the ability to metastasize. In such tumors, all 
cells that disseminate would have an increased likelihood of colonizing distant sites (35). 
Establishing lymph node metastases may be a more efficient process than establishing 
distant metastases and may therefore happen earlier and more frequently. This model would 
also be compatible with clinical observations, including the correlation between lymphatic 
and distant metastasis, the sometimes modest benefits of lymphadenectomy, and the 
advantage of early primary resection (assuming that even in such highly metastatic cancers, 
the survival rate of disseminated cells is relatively low, so that the tumor needs to grow to a 
certain size in order to metastasize efficiently).
Most metastases in our cohort were resected from the liver, which is the most frequent 
distant site of colorectal metastasis (36). Since venous blood from the intestines reaches the 
liver directly through the portal vein, it is possible that liver metastases are preferentially 
seeded hematogenously. Cancer cells that migrate through lymph nodes enter the venous 
circulation in the subclavian vein. The first capillary bed such cells encounter is the lung. It 
is therefore possible that lung metastases are more frequently seeded through the lymph 
nodes.
All cancers in our study were retrospectively collected specimens. Archival samples are 
mostly not suitable for whole genome or exome sequencing because patient consent for such 
comprehensive genetic profiling was not obtained at the time of surgery. Polyguanine repeat 
genotyping, on the other hand, is a limited analysis of length polymorphisms in non-coding 
DNA. It does not produce any information about functional or disease-related genes. Raw 
data produced by our method contain the lengths of PCR amplicons in arbitrary units, 
allowing for complete disclosure of mutation information while making patient 
identification impossible. Therefore, polyguanine repeat analysis represents a safe and 
effective method for studying tumor evolution in a patient population that would otherwise 
be inaccessible.
We conclude that the evolutionary relationship between lymphatic and distant metastases 
can take on two different forms in colorectal cancer. In the future, it will be important to 
determine whether cancers in the common and distinct origin categories exhibit different 
clinical behaviors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Tracing tumor evolution through indels in hypermutable DNA.
(A) Study design schematic. DNA samples from primary tumor (P), distant metastases (M), 
lymph node metastases (L) and normal tissue/germ line (N/GL) from 19 colorectal cancer 
patients were genotyped across 20-43 hypermutable polyguanine repeats. The genetic 
divergence between two samples is the average distance across all markers. Pairwise 
distances between all samples from a patient were used as input for phylogenetic 
reconstruction with the neighbor-joining algorithm. (B) Anatomical sketch and raw data 
example for a cancer (C38) with microsatellite instability. Mutations can be present in 
varying percentages of cells within a sample. Therefore, the distance of a tumor sample to 
the normal reference is a continuous value. The heatmap shows tumor-normal distances 
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across all samples and markers. Dark green, deletions. Purple, insertions. Note that the 
heatmap only shows a small part of the full data set for a patient. Pairwise distances between 
all samples are used for phylogenetic reconstruction. (C) Anatomical sketch and raw data 
example for a microsatellite stable cancer (C58). Heatmaps for all patients are provided in 
Fig. S13.
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Fig. 2. Common versus distinct origins of lymph node and distant metastases.
(A) Clonal expansions of single intestinal stem cells (ISCs) from children (age<15, n=12) 
have fewer polyguanine indels than clonal expansions from a 66-year old adult (n=6). Data 
are mean +/- standard error of the mean, two-tailed t-test. (B) Clonal mutation frequency in 
cancers (defined as JSD => 0.11 in 95% of tumor biopsies) is correlated with patient age at 
diagnosis. Normal ISCs on average have fewer polyguanine indels than age-matched 
cancers, but the two distributions overlap. Lines indicate the mean. (C) Most lymph node 
metastases are more closely related to the primary tumor than to distant metastases. The plot 
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shows d(L-M)/d(L-P)-1, the distance of each lymph node metastasis (L) to its closest distant 
metastasis (M), divided by its distance to its closest primary tumor sample (P), minus one. 
Yellow, closest neighbor is a metastasis. Dark blue, closest neighbor is a primary tumor 
sample. (D) Analogous plot for distant metastases, showing d(M-L)/d(M-P)-1 (E) 
Classification of patients into cases with common or distinct origins of lymphatic and distant 
metastases. (F) Bootstrap values reflecting origin classification confidence for each patient. 
(Bootstrap n=1000).
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Fig. 3. Phylogenetic trees of cancers with common origin of lymphatic and distant metastases.
All trees except C38 (MSI case) are drawn to scale and were constructed with the neighbor-
joining method. Seeding events (internal node/common ancestor and branches) that gave rise 
to distant metastases are shaded in red; events that gave rise to lymph node metastases are 
shaded in blue. Clinical information boxes show whether a patient received neoadjuvant 
therapy, whether primary tumor resection was complete (all margins unaffected), whether 
distant metastases occurred synchronously or metachronously, what percentage of suitable 
lymph nodes (i.e. those that were large and pure enough) was sampled, and the origin 
classification bootstrap value. Timelines summarize treatment and known lifespan for each 
patient. VI, venous invasion. Sat, satellite nodule. Lower case letters after sample numbers 
(a,b,c) indicate multiple biopsies from the same tumor mass. SOC, standard of care.
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Fig. 4. Phylogenetic trees of cancers with distinct origins of lymphatic and distant metastases.
All trees except C12 (MSI case) are drawn to scale and were constructed with the neighbor-
joining method. Shading and clinical information as in Figure 3.
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